AELIX Therapeutics has been awarded a grant by the Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades) through the 2017 RETOS-COLABORACIÓN call of the National Programme for Research, Development, and Innovation Addressing Society Challenges—within the framework of the National Plan for Scientific and Technological Research and Innovation 2013-2016.
AELIX Therapeutics is leading the consortium composed by Institut de Recerca de la Sida (IrsiCaixa) and Fundació Lluita Contra la Sida (FLS)
The project, “NUVATERA – Desarrollo de una nueva vacuna terapéutica contra el VIH” (Development of a novel therapeutic vaccine against HIV), with file number NUVATERA (RTC-2017-6473-1), is focused on the clinical development necessary to test the safety and efficacy of HTI strategy as a therapeutic vaccine against HIV in humans, and to be able to advance to the following phase II clinical trials.
RETOS-COLABORACIÓN program has endorsed this project in the form of a loan to AELIX Therapeutics (1.415.025 €), and grants to the two partners: IrsiCaixa (420.204 €) and FLS (643.860 €).
Aelix Therapeutics is supported by Spanish Government (Ministerio de Ciencia, Innovación y Universidades), Agencia Estatal de Investigación and FEDER Funds